What it sells
Synthetic biology platform of programmable engineered live bacteria that remodel the microenvironment of solid tumours so immunotherapy can reach immune-excluded tumours. Two pre-clinical programmes target colorectal, pancreatic and breast cancer.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-11-10 | — | €6.1M | — | eu-startups.com |
| 2026-11-10 | — | $6.8M | — | news.google.com |
| 2026-11-10 | — | $6.8M | — | news.google.com |
| 2026-11-10 | — | €6.1M | — | news.google.com |
| 2026-11-10 | Seed | $6.8M | — | pulse2.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-11-10.